Statement of Principles concerning hypersensitivity pneumonitis (Reasonable Hypothesis) (No. 7 of 2020)

The central legal mechanism in this instrument is the Statement of Principles model: the Repatriation Medical Authority identifies medical concepts and converts them into a closed list of factual factors which, if established and connected to a person’s relevant service, satisfy the statutory threshold of a reasonable hypothesis for claims under the VEA or MRCA. The core medical concept that the instrument addresses is hypersensitivity pneumonitis, which the instrument defines as a non‑infectious, immunological inflammation of lung parenchyma, secondary to inhalation by a sensitised subject of an external antigen (s7(2)(a)). The definition explicitly includes acute, subacute and chronic variants (s7(2)(b)) and excludes specified other lung conditions and non‑inhalational antigen exposures (s7(2)(c)).

A linked concept is “specific antigen responsible for the hypersensitivity pneumonitis”, which the Schedule defines as the antigen which the available clinical or laboratory evidence implicates as the cause in the patient. The Schedule also defines antigen in immunological terms, namely exogenous substances capable of stimulating type III or type IV non‑IgE hypersensitivity responses (Schedule 1). The Schedule provides non‑exhaustive examples of antigen sources such as bird droppings, mouldy timber dust, contaminated metalworking fluid, polyurethane varnishes containing diisocyanates, sewage sludge contaminated with micro‑organisms, detergent powder, and spores from Lycoperdon puffballs (Schedule 1, Note 1). These examples are illustrative; the Schedule’s wording makes clear that they are not limiting.

Causation is operationalised into three discrete factors in section 9, any one of which, if established and related to the person’s relevant service, meets the Statement’s minimum threshold: inhalation of the specific antigen before clinical onset (s9(1)); inhalation of the specific antigen within 30 days before clinical worsening (s9(2)); or inability to obtain appropriate clinical management for hypersensitivity pneumonitis (s9(3)). Section 10 narrows how those factors link to service. Subsection 10(1) requires that any factor be related to the person’s relevant service. Subsection 10(2) further restricts the application of factors 9(2) and 9(3) to cases where the person’s hypersensitivity pneumonitis was suffered or contracted before or during, but did not arise out of, the relevant service; in other words 9(2)-(3) apply only to material contribution or aggravation in pre‑existing disease that was not caused by the service.

The Statement also specifies that “death from hypersensitivity pneumonitis” includes deaths from terminal events or conditions that were contributed to by hypersensitivity pneumonitis (s7(5) and Schedule 1 terminal event definition). The instrument cross‑references ICD‑10‑AM code J67 but clarifies that for purposes of the Statement the statutory meaning is the text in s7(2) rather than the code alone (s7(3)-(4)).

The primary affected parties are claimants and potential claimants within the statutory frameworks identified: veterans, members of Peacekeeping Forces, members of the Forces under the VEA, and members under the MRCA whose claims fall within section 120A of the VEA or section 338 of the MRCA (s5 and s8). The Schedule explicitly defines “relevant service” to include operational service, peacekeeping, hazardous, British nuclear test defence service under the VEA, and warlike or non‑warlike service under the MRCA (Schedule 1). Therefore any person whose exposure or clinical course relates to one of those service types is within the substantive ambit where this Statement can be applied.

Medical practitioners and diagnosticians are affected in practice because the Statement turns clinical and laboratory findings into legally relevant evidentiary factors. The Schedule requires that the “specific antigen responsible” be the antigen implicated by available clinical or laboratory evidence; thus clinicians’ diagnostic processes, including history‑taking about exposures and any laboratory testing, are the factual materials that will feed the statutory causation test (Schedule 1). Decision‑makers who administer entitlements under the VEA and MRCA will apply this Statement when deciding whether a reasonable hypothesis exists for claims covered by the cited sections; while the instrument does not name particular decision bodies, its operation is explicitly tied to the statutory claims mechanisms in the VEA and MRCA (s3, s5).

Families and estates are also affected where death is at issue. The instrument treats “death from hypersensitivity pneumonitis” as including deaths from terminal events or conditions that were contributed to by the person’s hypersensitivity pneumonitis (s7(5) and Schedule 1 terminal event). This means that, in death claims, courts or decision‑makers may consider whether hypersensitivity pneumonitis contributed to a listed terminal event such as pneumonia or respiratory failure as part of the reasonable hypothesis test.

Finally, the Repatriation Medical Authority itself and, implicitly, other statutory actors interact with the instrument. The instrument came from the Authority exercising its statutory power under s196B(2) of the VEA (s3), and it also interacts with other Statements of Principles because s11 instructs that where a factor refers to an injury or disease already covered by another Statement, the factors in that other Statement apply according to its terms.

This instrument does not create new statutory penalties or direct obligations that resemble criminal or civil duties in the instrument itself. Instead it prescribes the legal standard and factual factors that determine when a reasonable hypothesis exists for the purposes of claims under specified provisions of the VEA and the MRCA. That transforms clinical and factual material into a threshold for entitlement decisions.

Rights and entitlements: a claimant who can establish one or more of the factors in section 9 and satisfy the relationship to relevant service in section 10 will have met the minimum requirement for a reasonable hypothesis connecting hypersensitivity pneumonitis or death from it to relevant service under the schemes referenced by sections 120A VEA and 338 MRCA. The Statement therefore functions as a template claim‑evidence standard that claimants may rely on when seeking acceptance of a condition as service‑related (s9-10).

Duties on evidence gathering and presentation: the Statement makes specific what evidence must be adduced. For example, the Schedule defines the “specific antigen responsible” as the antigen implicated by clinical or laboratory evidence. That definition shifts focus onto clinical/laboratory proof for factor 9(1) and 9(2), namely establishing inhalation of the specific antigen before onset or within 30 days of worsening (s9(1)-(2), Schedule 1). The third factor requires evidence that the claimant was unable to obtain appropriate clinical management for hypersensitivity pneumonitis (s9(3)). Those are factual prerequisites that evidence‑gathering must address.

Duties on decision‑makers: while the instrument itself is not a procedural code, it is made under s196B(2) of the VEA (s3) and is intended to be applied in adjudication of claims to which s120A VEA or s338 MRCA apply (s5). Decision‑makers in those claim processes will therefore have to assess whether the factors are present and related to relevant service. Section 11 imposes a duty to cross‑apply another Statement of Principles where a factor in this Statement refers to an injury or disease already covered by another Statement; in that situation the other Statement’s factors govern.

Limitations and conditionality: the Statement imposes limits on how factors can be used. Section 10(2) states that the inhalation within 30 days before clinical worsening and inability to obtain clinical management (s9(2)-(3)) only apply to material contribution or aggravation where the hypersensitivity pneumonitis was suffered or contracted before or during, but did not arise out of, the relevant service. That creates a conditional usage of those factors and places a duty on the adjudicator to consider timing and causation carefully.

Procedural rights such as review rights or appeal processes are not created or modified by this instrument; those procedural rights remain the responsibility of the VEA and MRCA frameworks to which the Statement applies. The Statement supplies an evidentiary floor for those processes.

This instrument does not prescribe penalties, fines, or criminal sanctions. Its enforcement mechanism is administrative rather than penal. The Statement of Principles operates as an evidentiary and causal standard to be used in the administration and adjudication of claims for entitlements under the VEA and MRCA. Enforcement therefore occurs through claim determinations and the statutory appeal and review mechanisms that apply to those determinations under the VEA and MRCA; the Statement itself does not set or alter those procedural routes.

Who enforces application of the Statement is implicit from the statutory context. The Repatriation Medical Authority made the Statement under subsection 196B(2) of the VEA (s3), and it is intended to be applied in claims to which section 120A of the VEA or section 338 of the MRCA applies (s5). The operational effect is that decision‑makers exercising functions under those Acts will use the Statement as the medical causation template for assessing whether a reasonable hypothesis exists that links hypersensitivity pneumonitis or related death to relevant service. The Statement binds the administrative process insofar as it is the Authority’s legislative instrument under the VEA. The instrument does not itself create new enforcement powers for the Authority beyond the statutory power to determine Statements of Principles.

The Statement contains no provisions that authorise inspection, compulsion of witnesses, or imposition of sanctions against medical practitioners or other third parties. The only listed consequences are in the context of claims adjudication: if the factual factors are or are not found, that will influence whether a claim reaches the reasonable hypothesis threshold, and therefore whether the claimant proceeds to entitlement on the statutory standards in the VEA and MRCA. The instrument does not specify standards of proof beyond the statutory “reasonable hypothesis” threshold; it sets the factual factors that satisfy that threshold.

In short, enforcement is procedural and administrative , the Statement is used to determine entitlement outcomes in the VEA/MRCA claims processes rather than to impose stand‑alone penalties.

This Statement is expressly made under subsection 196B(2) of the Veterans' Entitlements Act 1986 (s3), and it applies to claims falling under specific provisions of the VEA and the MRCA (s5). Consequently, its interaction with other law is principally through the claims frameworks of those Acts. The Statement does not amend the VEA or MRCA; it provides the Repatriation Medical Authority’s prescribed medical factors that decision‑makers apply when testing the statutory “reasonable hypothesis” threshold embedded in those Acts.

The instrument interacts with other Repatriation Medical Authority Statements of Principles by design. Section 11 provides that if a factor in this Statement refers to an injury or disease covered by another Statement of Principles determined under s196B(2) of the VEA, then the factors in that other Statement apply according to its terms. That creates a hierarchical or cross‑referential interaction where overlapping medical or causal matters are to be resolved by reference to the other Statement’s content as in force at the relevant time.

The Statement also interacts with medical classification systems through a specific ICD reference. Section 7(3) notes that hypersensitivity pneumonitis attracts ICD‑10‑AM code J67, but it clarifies that for applying the Statement the statutory meaning is the textual definition given in subsection 7(2). Section 7(4) specifies which edition of ICD‑10‑AM is referenced, namely The International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, Australian Modification, Tenth Edition, effective 1 July 2017, and identifies the Independent Hospital Pricing Authority ISBN for that edition. The instrument therefore uses the ICD code for classification convenience but makes the textual statutory definition determinative.

The Schedule defines “relevant service” in broad categories that map to statutory concepts in both the VEA and MRCA (Schedule 1). In practice this means the Statement will interact with the statutory definitions and eligibility frameworks for the classified service types under the VEA and MRCA. The instrument does not purport to change the meaning of those service categories; it applies the Statement to claims that already meet the service classification criteria in the relevant statutes.

Finally, by repealing the earlier Statement of Principles concerning extrinsic allergic alveolitis No. 87 of 2011 (s4), the instrument changes the authoritative medical template that applies to hypersensitivity pneumonitis and related claims going forward from commencement. That repeal is a direct statutory interaction affecting the body of RMA Statements of Principles.

The instrument itself contains minimal amendment history within its text. It was dated 28 February 2020 and it commences on 23 March 2020 (s1 header, s2). Its principal amendment action is the explicit repeal of the earlier Statement of Principles concerning extrinsic allergic alveolitis No. 87 of 2011 (s4). The 2011 instrument is identified by Federal Register of Legislation number F2011L01445 in the repeal clause, indicating that the 2011 Statement is removed from the corpus of Statements of Principles upon this instrument’s operation.

No subsequent amendments, variations, or revocation clauses are recorded in the text provided. The instrument does not itself provide for staged repeal, sunset, or periodic review in its text. Where the instrument refers to the application of factors in other Statements of Principles (s11), it expressly makes those other Statements apply “as in force from time to time”, which signals an awareness that Statements may change and that cross‑references will operate against the living text of other Statements.

The Schedule refers to a specific edition of ICD‑10‑AM (Tenth Edition, effective 1 July 2017) when characterising the code J67 (s7(4)). That cross‑reference fixes the classification reference point within the instrument but does not in itself constitute an amendment history. Any future changes to the ICD classification or later editions would not automatically change the statutory text; the instrument’s text remains authoritative until formally amended or repealed by the Authority under the statutory powers in the VEA.

In practice, amendment history for this instrument in the public record will be found by checking updates from the Repatriation Medical Authority and the Federal Register of Legislation where variations or repeals would be gazetted under the Authority’s statutory powers. The instrument does not set its own process for amendment; that process is the statutory function of the Authority under the VEA.

The instrument’s text does not record any litigation history. It is an administrative instrument that establishes an evidentiary standard for statutory claims processes under the VEA and the MRCA. Any litigation that engages this Statement would be external to the Statement’s text and would arise through administrative review or court challenges to decisions made under the VEA or MRCA where the Statement was applied.

Because the instrument sets factors that satisfy the legal threshold of a reasonable hypothesis, contested decisions are most likely to appear in appeal or review proceedings under the VEA or MRCA frameworks where a claimant or the respondent disputes whether the factors are present or properly related to relevant service. The Statement itself provides the legal template that a tribunal or court would interpret and apply when adjudicating such disputes, but the instrument contains no recorded cases or judicial interpretations in its text.

Users of this Statement should therefore expect that any litigation history relevant to interpretation and application will be found in the body of case law that discusses the application of Repatriation Medical Authority Statements of Principles to claims under the VEA and MRCA. This instrument does not cite or summarise such authorities. The Statement’s own provisions that are most likely to be litigated or litigated about include the meaning and sufficiency of “specific antigen responsible” in Schedule 1, the application and temporal limits of factors 9(2) and 9(3) as constrained by s10(2), and the interpretation of “inability to obtain appropriate clinical management” as a factor for material contribution or aggravation (s9-10, Schedule 1).

Absent case law in the instrument text, professionals should treat litigation history as an external research task: identify decisions that apply or interpret Statements of Principles generally, then test how tribunals and courts have handled the evidentiary and temporal thresholds that this Statement imposes.

Several provisions present practical traps for claimants and for those preparing or deciding claims. The instrument tightens medical‑fact to legal‑result links in specific ways, and those linkages merit careful attention.

1. Specific antigen requirement. Factors 9(1) and 9(2) require inhalation of the “specific antigen responsible for the hypersensitivity pneumonitis”. The Schedule defines that term as the antigen which the available clinical or laboratory evidence implicates as the cause (Schedule 1). This is not a generic exposure test. It requires clinical or laboratory evidence that connects a particular antigen to the patient’s disease. The Schedule’s examples of antigen sources are illustrative, not exhaustive (Schedule 1, Note 1). Practitioners should not assume that merely showing exposure to a common workplace allergen is sufficient; the evidentiary link to the specific antigen is central.

2. Temporal precision and limited use of aggravation factors. The instrument splits causation into onset and aggravation windows. Factor 9(1) requires inhalation before clinical onset. Factor 9(2) allows a 30‑day window before clinical worsening to establish material contribution to or aggravation of disease. Section 10(2) then restricts the latter two factors so that they only apply where the disease was suffered or contracted before or during, but did not arise out of, the relevant service. This means that 9(2) and 9(3) cannot be used to establish causation where the disease first arose out of the service; they only address material contribution or aggravation in pre‑existing disease. That limitation can be overlooked in claims where timing and causation are entangled.

3. “Inability to obtain appropriate clinical management” is a factor but is vague in practical terms. Section 9(3) lists inability to obtain appropriate clinical management for hypersensitivity pneumonitis as a standalone factor. The instrument does not define “appropriate clinical management”, and the only connection is that s10(2) restricts this factor to cases of material contribution or aggravation in pre‑existing disease. This creates evidentiary uncertainty: claimants must demonstrate both a failure to obtain appropriate management and that this failure materially contributed to worsening. The instrument leaves the standard of what counts as “appropriate” clinical management to clinical judgement applied in adjudication.

4. Death definition is contribution‑based. The Statement adopts a contribution standard for death. Subsection 7(5) and the Schedule’s “terminal event” definition mean that death from a terminal event (for example pneumonia, respiratory failure, cardiac arrest) qualifies if hypersensitivity pneumonitis contributed to it. The practical effect is that the cause of death need not be exclusively hypersensitivity pneumonitis, but claimants must show a contributory link.

5. ICD code is not determinative. Section 7(3) references ICD‑10‑AM code J67, but section 7(2) is the operative statutory definition. Do not treat the ICD code alone as sufficient to meet the Statement’s legal standard. The instrument expressly separates classification coding from the statutory meanings it uses for adjudication.

6. Cross‑references to other Statements. Section 11 requires adopting factors from other Statements of Principles when a factor refers to an injury or disease covered by those Statements. Practitioners should check whether an asserted factor implicates another Statement and then apply the current version of that other Statement “as in force from time to time”. Failure to do so risks misapplying an overlapping Statement.

7. Repeal timing. The instrument repeals the 2011 Statement. Claims with earlier events may raise questions about which Statement applies if facts straddle the repeal date. The instrument’s commencement date is 23 March 2020; any transition issues will need careful factual analysis against claim dates and service periods.

8. Narrow immunology definition. The Schedule defines antigen in terms of type III or type IV, non‑IgE responses. That definition excludes IgE mediated disease mechanisms and non‑inhalational antigen pathways (s7(2)(c) excludes ingested drugs and acute anaphylaxis). Claimants whose pulmonary symptoms are mediated by different immunopathology may fall outside this Statement.

9. Burden of proof sits with claimant in practical terms. While the Statement defines what constitutes a reasonable hypothesis, establishing those factors in evidence is a practical task for the claimant within the claims process. The instrument’s design pushes claimants toward clinical and laboratory proof of specific antigens and timeline evidence for onset or worsening.

Compliance in this context means assembling and presenting the factual and clinical evidence that matches the Statement’s factors and the relationship to service requirements at sections 9 and 10. The instrument prescribes discrete evidentiary objectives. Practical steps, grounded in the instrument’s terms, are as follows.

1. Match evidence to the factor categories. For factor 9(1), assemble clinical and laboratory evidence that links inhalation of a specific antigen to the clinical onset of hypersensitivity pneumonitis. The Schedule requires that the “specific antigen responsible” be the antigen implicated by available clinical or laboratory evidence (Schedule 1). For factor 9(2), document inhalation of the implicated antigen within the 30 days before a documented clinical worsening. For factor 9(3), document attempts to obtain appropriate clinical management and provide evidence that those attempts failed such that the lack of management materially contributed to worsening. Ensure the factual narrative mirrors the statutory phraseology: “inhaling the specific antigen responsible” and the 30‑day window for worsening.

2. Obtain clinical and laboratory testing where possible. The Schedule links the “specific antigen responsible” to what the available clinical or laboratory evidence implicates (Schedule 1). To satisfy that linkage, consider obtaining specialist respiratory assessments, immunological testing, imaging, bronchoalveolar lavage, biopsy reports where clinically indicated, and any laboratory identification of antigens or micro‑organisms. Label and date the clinical records so that onset and worsening timelines are clear and can be compared to service‑period exposure records.

3. Document service exposure with specificity. Because the Statement requires that any factor be related to the person’s relevant service (s10(1)), assemble contemporaneous service records, duty statements, lodging reports, and any logs or incident reports that identify the nature, timing and location of exposures to potential antigen sources listed in the Schedule (for example bird droppings, mouldy timber dust, contaminated metalworking fluid) or to other plausible inhalational antigens. Tie those records to clinical dates of onset or worsening.

4. If relying on aggravation factors 9(2) or 9(3), confirm pre‑existence and non‑causal origin. Section 10(2) restricts 9(2) and 9(3) to scenarios where hypersensitivity pneumonitis was suffered or contracted before or during, but did not arise out of, the relevant service. To use those factors, produce evidence that the disease pre‑existed or was contracted during service and that the service did not originate the disease; then show how exposure during service or inability to obtain management materially contributed to or aggravated the condition.

5. For death claims, document contribution to terminal events. When a claim involves death, use clinical records, cause of death documentation and expert opinion to show that hypersensitivity pneumonitis contributed to a listed terminal event (for example pneumonia or respiratory failure) as defined in the Schedule (s7(5) and Schedule 1 terminal event). The Statement accepts contribution as sufficient, so the evidence should explain the contribution mechanism.

6. Check for cross‑referenced Statements. If any factor implicates an injury or disease covered by another Statement of Principles, follow section 11 and apply the other Statement’s factors “as in force from time to time”. Identify whether contemporaneous or superseding Statements affect the factual pathways relied on, and obtain evidence that meets those other Statements where required.

7. Be precise about the immunological mechanism. The Schedule defines antigen in terms of type III or IV non‑IgE responses. If clinical opinion identifies an IgE pathway or a non‑inhalational exposure mechanism, recognise that this Statement excludes such mechanisms (s7(2)(c) excludes ingested and non‑inhalational antigen exposures, and Schedule 1 defines antigen by type III and IV responses).

8. Prepare expert opinion that ties clinical facts to the statutory factors. The Statement’s causal standard is factually driven; properly directed expert opinion that links the clinical evidence, laboratory results and exposure history to the instrument’s factor wording will be directly relevant. Experts should frame their evidence in the language of the Statement: whether the specific antigen was inhaled before onset, whether inhalation occurred within 30 days of worsening, whether appropriate management was unavailable, and how those facts relate to relevant service.

9. Maintain chronological clarity. The Statement’s distinctions depend on timing: onset, worsening within 30 days, and pre‑existence versus arising out of service. Ensure clinical records, service records and any exposure logs are synchronised and annotated so adjudicators can match events to the statutory temporal windows.

10. Preserve records of attempts to obtain treatment. For factor 9(3) evidence of inability to obtain appropriate clinical management must be specific. Preserve referrals, appointment attempts, correspondence, policy decisions or access barriers that document why appropriate care was not received. These records will be necessary to establish material contribution through lack of management.

Following these steps aligns evidentiary practice to the instrument’s text and the Repatriation Medical Authority’s definitions. The Statement is factual and narrowly worded. Compliance requires organising clinical, laboratory and service evidence so that each asserted factor is demonstrably present and is related to the person’s relevant service per section 10.